The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Comorbid Diseases in Nonalcoholic fatty liver disease

비알코올성 지방간질환의 병발 질환

  • Yoon, Min-Yong (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Cho, Yong-Kyun (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 윤민용 (성균관대학교 의과대학 강북삼성병원 내과학교실) ;
  • 조용균 (성균관대학교 의과대학 강북삼성병원 내과학교실)
  • Published : 2010.11.01
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a wide spectrum of diseases that are ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NAFLD has been recognized as a hepatic feature of metabolic syndrome linked with insulin resistance. Recent evidence supports that NAFLD is associated with numerous systemic diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, obesity, metabolic syndrome. Therefore, NAFLD should be newly considered not only an liver specific disease, but also early mediator of systemic metabolic disease. The underlying mechanism and pathogenesis of harmful effect of NAFLD on other medical disorders are yet to be fully understood and major questions remain that must be solved to decreased morbidity and mortality from the spectrum of NAFLD. So further research is needed for future therapeutic strategies of NAFLD. This review focuses on the relationship between NAFLD and various comorbid disease.

Keywords

References

  1. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 21:138-143, 2006 https://doi.org/10.1111/j.1440-1746.2005.04086.x
  2. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25:1045-1050, 2005 https://doi.org/10.1161/01.ATV.0000160613.57985.18
  3. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 121:72-78, 2008 https://doi.org/10.1016/j.amjmed.2007.08.041
  4. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27:2498-2500, 2004 https://doi.org/10.2337/diacare.27.10.2498
  5. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42:473-480, 2005 https://doi.org/10.1002/hep.20781
  6. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1):III27-III32, 2004
  7. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22:437-443, 2006 https://doi.org/10.1002/dmrr.666
  8. Kim DH, Choi SY, Park EH, Yang JI, Kim W, Kim YJ, Yoon JH, Lee HS, Shin CS, Cho SH, Oh BH. Non-alcoholic fatty liver disease (NAFLD) as a risk factor of coronary heart disease; relation of NAFLD to coronary artery calcification score by multi- detector computed tomography: The 43rd Annual Meeting of the European Association for the Study of the Liver Milan, Italy, 2008
  9. Pitsavos C, Panagiotakos DB, Skoumas J, Papadimitriou L, Stefanadis C. Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study. Angiology 59:335-341, 2008 https://doi.org/10.1177/0003319707307273
  10. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 26:406-410, 2006
  11. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 264:30-38, 2008 https://doi.org/10.1111/j.1365-2796.2008.01925.x
  12. Lee JA, Jang SH, Min JH, Kim TW, Jeong WS, Shim CN, Heo WJ, Jung MJ, Lee HA, Cho YK, Hong HP. The relationship between the ApoB/ApoA-I ratio and non-alcoholic fatty liver disease in prediabetic patients. Korean J of Med 78:191-197, 2010
  13. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med 23:403-409, 2006 https://doi.org/10.1111/j.1464-5491.2006.01817.x
  14. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 5:287-295, 2005 https://doi.org/10.2174/1566524053766031
  15. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40(Suppl 1):S17-S29, 2006
  16. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16:421-427, 2005 https://doi.org/10.1097/01.mol.0000174153.53683.f2
  17. Neuschwander-Teri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330:326-335, 2005 https://doi.org/10.1097/00000441-200512000-00011
  18. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004 https://doi.org/10.1161/01.ATV.0000099786.99623.EF
  19. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004 https://doi.org/10.1001/jama.291.14.1730
  20. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164-176, 2005 https://doi.org/10.2337/diacare.28.1.164
  21. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51:714-725, 2008 https://doi.org/10.1007/s00125-008-0961-8
  22. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-174, 2004 https://doi.org/10.7326/0003-4819-140-3-200402030-00007
  23. Lin CC, Liu CS, Li TC, Chen CC, Li CI, Lin WY. Microalbuminuria and the metabolic syndrome and its components in the Chinese population. Eur J Clin Invest 37:783-790, 2007 https://doi.org/10.1111/j.1365-2362.2007.01865.x
  24. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 19:1564-1570, 2008 https://doi.org/10.1681/ASN.2007101155
  25. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, Jung E, Kim WS. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 57:569-576, 2008 https://doi.org/10.1016/j.metabol.2007.11.022
  26. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ, Oh KW, Lee WY, Jin W. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 40:437-442, 2010 https://doi.org/10.1111/j.1445-5994.2009.01979.x
  27. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 39:1-11, 2002 https://doi.org/10.1053/ajkd.2002.29865
  28. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59:1498-1509, 2001 https://doi.org/10.1046/j.1523-1755.2001.0590041498.x
  29. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 55:123-130, 2006 https://doi.org/10.1136/gut.2005.069757
  30. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45:80-87, 2007 https://doi.org/10.1002/hep.21455
  31. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358-1364, 2001 https://doi.org/10.1053/jhep.2001.24432
  32. Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44:1648-1655, 2006 https://doi.org/10.1002/hep.21429
  33. Gabriel A, Ziolkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res 38:141-146, 2008
  34. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 11:91-96, 2004 https://doi.org/10.1046/j.1365-2893.2003.00483.x
  35. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132-138, 2005
  36. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999 https://doi.org/10.1016/S0016-5085(99)70506-8
  37. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873, 2006 https://doi.org/10.1002/hep.21327
  38. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923, 2003 https://doi.org/10.1053/jhep.2003.50161
  39. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 143:722-728, 2005 https://doi.org/10.7326/0003-4819-143-10-200511150-00009
  40. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850, 2001 https://doi.org/10.2337/diabetes.50.8.1844
  41. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effect of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferase, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Heptol 38:434-440, 2003 https://doi.org/10.1016/S0168-8278(03)00027-8
  42. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002 https://doi.org/10.1056/NEJMra011775
  43. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001 https://doi.org/10.1053/gast.2001.25540
  44. Adams LA, Harmsen WS, St Sauver JL, Charatcharoewitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increase risk of death among patient with diabetes: a community-based cohort study Am J Gastroenterol 105:1567-1573, 2010 https://doi.org/10.1038/ajg.2010.18
  45. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028, 2002 https://doi.org/10.1210/jc.87.7.3023
  46. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108:9-13, 2000
  47. Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 39:864-869, 2004 https://doi.org/10.1080/00365520410006431
  48. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of non-alcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22:1086-1091, 2007 https://doi.org/10.1111/j.1440-1746.2006.04781.x
  49. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30:2940-2944, 2007 https://doi.org/10.2337/dc07-0792